|
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with adjuvant chemotherapy |
||||
| Genotype |
Cases |
Deaths |
Hazard ratio minimally adjusteda (95% confidence interval) |
Hazard ratio fully adjustedb (95% confidence interval) |
|
|
||||
| Overall survival |
230 |
75 |
P for trend = 0.46 |
P for trend = 0.42 |
| CC |
140 |
49 |
1 (reference) |
1 (reference) |
| CT |
73 |
21 |
0.83 (0.49–1.38) |
0.67 (0.38–1.17) |
| TT |
17 |
5 |
0.81 (0.32–2.04) |
1.07 (0.42–2.74) |
| CC |
140 |
49 |
1 (reference) |
1 (reference) |
| CT + TT |
90 |
26 |
0.82 (0.51–1.33) |
0.73 (0.44–1.22) |
| Recurrence-free survival |
220 |
85 |
P for trend = 0.16 |
P for trend = 0.12 |
| CC |
136 |
57 |
1 (reference) |
1 (reference) |
| CT |
68 |
24 |
0.79 (0.49–1.28) |
0.64 (0.38–1.07) |
| TT |
16 |
4 |
0.55 (0.20–1.52) |
0.73 (0.26–2.049) |
| CC |
136 |
57 |
1 (reference) |
1 (reference) |
| CT + TT |
84 |
28 |
0.75 (0.47–1.18) |
0.65 (0.40–1.05) |
|
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status. | ||||
Martin et al. Breast Cancer Research 2006 8:R45 doi:10.1186/bcr1532 |
||||